Other research groups indicate that SRC‐mediated ERK reactivation may play a role in gefitinib resistance mechanism of EGFR‐mutant NSCLC cells, or that constitutively active SRC increased gemcitabine chemoresistance in contrast to dominant negative SRC that impaired gemcitabine chemoresistance of pancreatic adenocarcinoma cells (Ochi et al., 2014) (Duxbury et al., 2004). This evidence concerns the gene SRC and non-small cell lung carcinoma.